DexCom (NASDAQ:DXCM) Raised to Outperform at Robert W. Baird

DexCom (NASDAQ:DXCM) was upgraded by Robert W. Baird from a “neutral” rating to an “outperform” rating in a note issued to investors on Thursday, Marketbeat Ratings reports. The firm currently has a $104.00 price target on the medical device company’s stock, up from their previous price target of $86.00. Robert W. Baird’s price target indicates a potential upside of 23.25% from the company’s current price.

DXCM has been the subject of a number of other reports. Royal Bank of Canada decreased their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. JPMorgan Chase & Co. upped their price objective on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Oppenheimer lowered their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Leerink Partners dropped their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Finally, Canaccord Genuity Group raised their price objective on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.29.

DexCom Trading Down 0.5 %

Shares of NASDAQ:DXCM opened at $84.38 on Thursday. The company has a 50 day moving average of $78.17 and a 200-day moving average of $78.22. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The firm has a market cap of $32.96 billion, a P/E ratio of 50.53, a P/E/G ratio of 2.00 and a beta of 1.12. DexCom has a twelve month low of $62.34 and a twelve month high of $142.00.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On DexCom

Large investors have recently made changes to their positions in the business. Versant Capital Management Inc acquired a new stake in shares of DexCom during the fourth quarter worth approximately $25,000. Riverview Trust Co lifted its position in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after buying an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new stake in shares of DexCom during the 3rd quarter valued at $57,000. Covestor Ltd grew its holdings in shares of DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after acquiring an additional 335 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its stake in shares of DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after acquiring an additional 265 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.